|
|
|
Market Research Report
Men's Health: The Market for Current and Emerging Drug Therapies, 2nd Edition
| Published by |
Kalorama Information |
| Published |
May, 2006 |
Product code |
41730 |
| Content info |
234 pages |
| Price |
|
|
Men's Health: The Market for Current and Emerging Drug Therapies, 2nd Edition published by Kalorama Information in May, 2006. This report consists of 234 pages and the price starts from US $ 3500.
Abstract
This complete re-evaluation of the Men's Health market focuses on the
following prescription drug treatment segments:
- Men's Cancer
- Men's Sexual Dysfunction
- Men's Sexually Transmitted Diseases
- Men's Urinary Conditions
- Andropause
The report covers drugs used for the treatment of prostate cancer, testicular
cancer, impotence, premature ejaculation, and benign prostatic hyperplasia
(BPH), urinary incontinence, and STD's such as HIV, herpes, and genital warts.
For each segment, revenues and forecasts are made by type of drug through
2010; competitive market share of the leading suppliers are estimated for 2005
and projected to 2010 based on likely market entrants and patent expiry; and a
geographical breakdown (U.S. vs non-U.S.) is provided through 2010.
The report includes epidemiologic information on the various conditions (U.S.
and worldwide) and reviews the issues and trends-business, clinical,
regulatory, and social-that are shaping the future of this market.
Table of Contents
Chapter One: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
Chapter Two: Introduction
- History and Growth of the Men's Health Industry
- Male Anatomy
- Male Reproductive Physiology
- Male Demographics and Statistics
chapter Three: Men's Cancer
- Overview
- Description of Cancers Affecting Men
- Prostate Cancer
- Testicular Cancer
- Prevalence and Incidence
- Description of Products
- Hormone Therapies
- LHRH Analogs
- Antiandrogens
- Intermittent Hormone Therapy
- Adjuvant Hormone Therapy
- Chemotherapy Agents
- Brachytherapy
- Research and Development
- Market Size and Growth
- World Market
- U.S. Market
- Non-U.S. Market
- Competitive analysis
chapter Four: Male Sexual Dysfunction
- Overview
- Description of Sexual Disorders Affecting Men
- Erectile Dysfunction
- Ejaculation Disorders
- Prevalence and Incidence
- Description of Products
- Phosphodiesterase Type V Inhibitors (PDE-5 Inhibitors)
- Others
- Research and Development
- Market Size and Growth
- World Market
- U.S. Market
- Non-U.S. Market
- Competitive Analysis
chapter Five: Sexually Transmitted Diseases
- Overview
- Description of Sexually Transmitted Diseases Affecting Men
- Chlamydia
- Genital Herpes
- Genital Warts
- Gonorrhea
- HIV/AIDS
- Syphilis
- Prevalence and Incidence
- Description of Products
- Antibiotics
- Antiviral Therapies
- Others
- Research and Development
- Market Size and Growth
- World Market
- U.S. Market
- Non-U.S. Market
- Competitive Analysis
chapter Six: Men's Urinary Conditions
- Overview
- Description of Urinary Conditions Affecting Men
- Benign Prostate Hypertrophy (BPH)
- Prostatitis
- Urinary Incontinence
- Prevalence and Incidence
- Description of Products
- Alpha Blockers
- 5-Alpha Reductase Inhibitors
- Anticholinergics
- Antispasmodics and Others
- Research and Development
- Market Size and Growth
- World Market
- U.S. Market
- Non-U.S. Market
- Competitive Analysis
chapter Seven: Male Menopause or Andropause
- Overview
- Description of Male Menopause
- Prevalence and Incidence
- Description of Products
- Research and Development
- Market Size and Growth
- World Market
- U.S. Market
- Non-U.S. Market
- Competitive Analysis
Chapter Eight: Issues and Trends Affecting the Men's Health Market
- Introduction
- Education and Awareness of Men's Health
- Office of Men's Health
- Changing Life Expectancy
- Diabetes and Sleep
- Early Detection and Screening of Prostate Cancer
- Blacks and Prostate Cancer
- Erectile Dysfunction and CAD
- Cosmetic Surgery
- Bladder Cancer Detection
- Lifestyle Changes and Prostate Cancer
- Effects of Testosterone Dosage on Behavior of Older Men
- Testosterone Replacement Therapy Decreases Fat and Increases Muscle
- Men of All Ages Respond to Building Muscle Mass with Testosterone Doses
Chapter Nine: Market Summary
- Overview
- Market Size and Forecast
- World Market
- Markets by Segments
- Competitor Analysis
- Market Outlook
chapter Ten: Corporate Profiles
- Introduction
- Current Market Leaders Profiles
- Abbott Laboratories
- Astellas Pharma Inc.
- ALZA Corporation
- AstraZeneca plc
- Bayer Corporation
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Eli Lilly & Company
- GlaxoSmithKline plc
- Merck & Company, Inc.
- Pfizer, Inc.
- Roche Group
- Sanofi-Aventis
- Takeda Chemical Industries, Ltd.
- TAP Pharmaceutical Products, Inc.
- Unimed Pharmaceuticals, Inc.
- VIVUS, Inc.
- Watson Pharmaceuticals, Inc.
Appendix: Company Directory
List of Exhibits
Chapter One: Executive Summary
- Table 1-1: The World Market for Men's Health Prescription Drugs 2003-2010
- Figure 1-1: Trending in the World Market Men's Health, 2003-2010
Chapter Two: Introduction
- Table 2-1: World Male Population by Selected Geographical Region 2005-2050
- Table 2-2: Life Expectancy at Birth by Selected Countries, 2000
- Table 2-3: United States Life Expectancy at Birth, 1990-2000, and
Projections, 2005-2010
- Table 2-4: Estimated Male Prevalence of Selected Risk Behavior by
Geographical Region, 2005
- Figure 2-1: Estimated Male Prevalence of Selected Risk Behavior by
Geographical Region, 2005
chapter Three: Men's Cancer
- Table 3-1: Men's Cancer: Estimated World Incidence and Prevalence
- Figure 3-1: Men's Cancer: World Incidence
- Table 3-2: Research and Development in Men's Cancer Therapies (Product,
Developer, Phase, Drug Class, Projected Approval Date)
- Table 3-3: The World Market Men's Health: Men's Cancer Therapies by
Product Type (Hormone Therapy, Chemotherapy) 2003-2010
- Figure 3-2: Trending in the World Market for Men's Cancer Therapies
2003-2010
- Table 3-4: The U.S. Market Men's Cancer Therapies 2003-2010
- Figure 3-3: Trending in the U.S. Market for Men's Cancer Therapies
2003-2010
- Table 3-5: The International (Non-U.S.) Market for Men's Cancer Therapies
2003-2010
- Figure 3-4: Trending in the International (Non-U.S.) Market for Men's
Cancer Therapies, 2003-2010
- Table 3-6: Leading Suppliers' Revenues and Market Shares of the World
Market for Men's Cancer Therapies Estimated 2005 and Projected 2010
- Figure 3-5: Leading Suppliers Market Share of the World Market for Men's
Cancer Therapies, 2005 and 2010
chapter Four: Male Sexual Dysfunction
- Table 4-1: Estimated World and U.S. Incidence and Prevalence of Male
Sexual Dysfunction by Type (Erectile Dysfunction, Premature Ejaculation)
- Figure 4-1: World Prevalence of Men's Sexual Dysfunction
- Table 4-2: PDE-5 Inhibitor Comparison Chart
- Table 4-3: Research and Development in Men's Sexual Dysfunction (Product,
Developer, Phase, Drug Class, Projected Approval Date)
- Table 4-4: The World Market Men's Sexual Dysfunction Therapies by Product
Type (PDE-5 Inhibitors and Others) 2003-2010
- Figure 4-2: Trending in the World Market for Men's Sexual Dysfunction
Therapies 2003-2010
- Table 4-5: The U.S. Market for Men's Sexual Dysfunction Therapies 2003-2010
- Figure 4-3: Trending in the U.S. Market for Men's Sexual Dysfunction
Therapies 2003-2010
- Table 4-6: The International (Non-U.S.) Market for Men's Sexual
Dysfunction Therapies 2003-2010
- Figure 4-4: Trending in the International (Non-U.S.) Market for Men's
Sexual Dysfunction Therapies 2003-2010
- Table 4-7: Leading Suppliers' Revenues and Market Shares of the World
Market for Men's Sexual Dysfunction Therapies Estimated 2005 and Projected 2010
- Figure 4-5: Leading Suppliers' Market Shares of the World Market for Men's
Sexual Dysfunction Therapies, 2005 and 2010
chapter Five: Sexually Transmitted Diseases
- Table 5-1: Men's Sexually Transmitted Diseases: Estimated World Incidence
- and Prevalence for Men (in thousands)
- Figure 5-1: Men's Sexually Transmitted Diseases: World Incidence
- Table 5-2: Research and Development in Sexually Transmitted Disease
Therapeutics (Product, Developer, Phase, Drug Class, Indication, Projected
Approval Date for Phase III)
- Table 5-3: The World Market Men's Sexually Transmitted Disease Therapies
by Product Type (Antibiotics, Antivirals, Others) 2003-2010
- Figure 5-2: Trending in the World Market for Men's Sexually Transmitted
Disease Therapies 2003-2010
- Table 5-4: The U.S. Market Men's Sexually Transmitted Disease Therapies
2003-2010
- Figure 5-3: Trending in the U.S. Market for Men's Sexually Transmitted
Disease Therapies, 2003-2010
- Table 5-5: The International (Non-U.S.) Market for Men's Sexually
Transmitted Disease Therapies 2003-2010
- Figure 5-4: Trending in the International (Non-U.S.) Market for Men's
Sexually Transmitted Disease Therapies 2003-2010
- Table 5-6: Leading Suppliers' Revenues and Market Shares of the World
Market for Men's Sexually Transmitted Disease Therapies Estimated 2005 and
Projected 2010
- Figure 5-5: Leading Suppliers' Market Shares of the World Market for Men's
Sexually Transmitted Disease Therapies 2005 and 2010
chapter Six: Men's Urinary Conditions
- Table 6-1: Estimated World Incidence and Prevalence for Men's Urinary
- Conditions (BPH and Urinary Incontinence; in thousands)
- Figure 6-1: Men's Urinary Conditions: World Prevalence
- Table 6-2: Research and Development in Urinary Condition Therapeutics
(Product, Developer, Phase, Drug Class, Indication, Projected Approval Date
for Phase III)
- Table 6-3: The World Market Men's Urinary Condition Therapies by Product
Type (Hormone Therapy, Chemotherapy) 2003-2010
- Figure 6-2: Trending in the World Market for Men's Urinary Condition
Therapies 2003-2010
- Table 6-4: The U.S. Market for Men's Urinary Condition Therapies 2003-2010
- Figure 6-3: Trending in the U.S. Market for Men's Urinary Condition
Therapies 2003-2010
- Table 6-5: The International (Non-U.S.) Market for Men's Urinary Condition
Therapies 2003-2010
- Figure 6-4: Trending in the International (Non-U.S.) Market for Men's
Urinary Condition Therapies 2003-2010
- Table 6-6: Leading Suppliers' Revenues and Market Shares of the World
Market for Men's Urinary Condition Therapies Estimated 2005 and Projected 2010
- Figure 6-5: Leading Suppliers Market Shares of the World Men's Urinary
Condition Therapies Market 2005 and 2010
chapter Seven: Male Menopause or Andropause
- Table 7-1: Estimated World Incidence and Prevalence of Andropause (in
thousands)
- Figure 7-1: World Prevalence of Andropause (Low and High Range)
- Table 7-2: Research and Development in Sexually Transmitted Disease
Therapeutics (Product, Developer, Phase, Drug Class, Projected Approval Date)
- Table 7-3: The World Market for Andropause Therapies 2003-2010
- Figure 7-2: Trending in the World Market for Andropause Therapies
2003-2010 Table 7-4: The U.S. Market for Andropause Therapies 2003-2010
- Figure 7-3: Trending in the U.S. Market for Andropause Therapies 2003-2010
- Table 7-5: The International (Non-U.S.) Market for Andropause Therapies
2003-2010
- Figure 7-4: Trending in the International (Non-U.S.) Market for Andropause
Therapies 2003-2010
- Table 7-6: Leading Suppliers' Revenues and Market Shares of the World
Market for Andropause Therapies Estimated 2005 and Projected 2010
Chapter Eight: Issues and Trends Affecting the Men's Health Market
- Table 8-1: Relative Risk Related to Family History of Prostate Cancer
Chapter Nine: Market Summary
- Table 9-1: The World Market for Men's Health Prescription Drugs 2003-2010
- Table 9-2: The World Market for Men's Health Prescription Drugs by Segment
(Men's Cancer, Sexual Function, Sexually Transmitted Diseases, Urinary
Conditions, Andropause) 2003-2010
- Figure 9-1: Trending in the World Market for Men's Health Therapeutics
2003-2010
- Figure 9-2: Distribution of Revenues in the World Market for Men's Health
Therapeutics by Product Type 2005
- Table 9-4: Leading Suppliers and Significant Segments of Participation 2005
|
 |
